IMAGO BIOSCIENCES INC (IMGO) Stock Price, Quote, News and Overview
NASDAQ:IMGO - Nasdaq - US45250K1079 - Common Stock - Currency: USD
IMGO Quote, Performance and Key Statistics
36.01
+0.01 (+0.03%)
The current stock price of IMGO is 36.01 USD. In the past month the price increased by 0.25%. In the past year, price increased by 94.86%.
IMGO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About IMGO
Company Profile
Imago BioSciences, Inc. operates as a clinical-stage biopharmaceutical company that develops novel anti-cancer therapeutics. The company is headquartered in Redwood City, California and currently employs 41 full-time employees. The company went IPO on 2021-07-16. The firm is engaged in discovering and developing small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. The company focuses on providing treatment for patients with cancer and bone marrow diseases. The Company’s lead product candidate is bomedemstat, which is developed for the treatment of myeloproliferative neoplasms (MPNs), a chronic cancer of the bone marrow. The Company’s product candidate, bomedemstat, is in Phase II clinical trial for the treatment of essential thrombocythemia (ET). The firm also develops bomedemstat and other LSD1-targeting product candidates for additional indications in areas of unmet medical need. The company tests bomedemstat in mouse models of MPNs as a single agent.
Company Info
IMAGO BIOSCIENCES INC
303 Twin Dolphin Drive, 6Th Floor
Redwood City CALIFORNIA US
CEO: Hugh Y. Rienhoff
Employees: 41
Company Website: https://www.imagobio.com/
Phone: 14155295055.0
IMAGO BIOSCIENCES INC / IMGO FAQ
What is the stock price of IMAGO BIOSCIENCES INC today?
The current stock price of IMGO is 36.01 USD. The price increased by 0.03% in the last trading session.
What is the ticker symbol for IMAGO BIOSCIENCES INC stock?
The exchange symbol of IMAGO BIOSCIENCES INC is IMGO and it is listed on the Nasdaq exchange.
On which exchange is IMGO stock listed?
IMGO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for IMAGO BIOSCIENCES INC stock?
11 analysts have analysed IMGO and the average price target is 36.72 USD. This implies a price increase of 1.97% is expected in the next year compared to the current price of 36.01. Check the IMAGO BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is IMAGO BIOSCIENCES INC worth?
IMAGO BIOSCIENCES INC (IMGO) has a market capitalization of 1.22B USD. This makes IMGO a Small Cap stock.
How many employees does IMAGO BIOSCIENCES INC have?
IMAGO BIOSCIENCES INC (IMGO) currently has 41 employees.
What are the support and resistance levels for IMAGO BIOSCIENCES INC (IMGO) stock?
IMAGO BIOSCIENCES INC (IMGO) has a support level at 35.97 and a resistance level at 36.02. Check the full technical report for a detailed analysis of IMGO support and resistance levels.
Should I buy IMAGO BIOSCIENCES INC (IMGO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IMGO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IMGO, evaluating the profitability, health, valuation and growth aspects
- IMAGO BIOSCIENCES INC (IMGO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- IMAGO BIOSCIENCES INC (IMGO) Sales and EPS estimates to see what analysts future expectations are.
- IMAGO BIOSCIENCES INC (IMGO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- IMAGO BIOSCIENCES INC (IMGO) Insider and Institutional Ownership to learn about the owners and their transactions.
- IMAGO BIOSCIENCES INC (IMGO) Stock Chart to make your own analysis
- IMAGO BIOSCIENCES INC (IMGO) Latest news and press-releases to stay up to date.
Does IMAGO BIOSCIENCES INC (IMGO) stock pay dividends?
IMGO does not pay a dividend.
What is the Price/Earnings (PE) ratio of IMAGO BIOSCIENCES INC (IMGO)?
IMAGO BIOSCIENCES INC (IMGO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.84).
IMGO Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to IMGO. When comparing the yearly performance of all stocks, IMGO is one of the better performing stocks in the market, outperforming 99.04% of all stocks.
IMGO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IMGO. While IMGO has a great health rating, there are worries on its profitability.
IMGO Financial Highlights
Over the last trailing twelve months IMGO reported a non-GAAP Earnings per Share(EPS) of -1.84. The EPS decreased by -69.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
IMGO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 51% to IMGO. The Buy consensus is the average rating of analysts ratings from 11 analysts.